- CEO
- Can Wen Huang
- Full Time Employees
- 1,028
- Sector
- Non-energy minerals
- Industry
- Construction materials
- Address
- Office Building 1, Chengdu International Finance Center Chengdu SI China 610021
- IPO Date
- Aug 24, 1999
- Business
- Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) is a China-based company principally engaged in industrial investment management and private equity investment fund management; it manages assets encompassing building materials manufacturing, CNI biomedicine R&D and production, and private equity fund operations through its subsidiary Tibet Jinhe, which oversees funds totaling nearly CNY 28 billion invested in biomedical, advanced manufacturing, artificial intelligence, clean energy, self-driving cars, and other emerging sectors. The company produces and sells cement, commercial clinker, and aggregates for applications in roads, railways, airports, power stations, real estate, municipal infrastructure, and rural construction; through its acquired biomedicine assets, it offers peptide active pharmaceutical ingredients including GLP-1 drugs such as semaglutide, tirzepatide, and liraglutide, peptide contract development and manufacturing organization (CDMO) services, and cosmetic peptides. Founded in 1998 and headquartered in Chengdu, Sichuan Province, the company primarily operates in China with export activities to Southeast Asia and the Middle East; it was formerly known as Sichuan Shuangma Cement Co., Ltd. and changed its name in February 2022. In late 2024, Sichuan Hexie Shuangma completed the acquisition of 92.17% equity in Shenzhen Jianyuan Technology Co., Ltd. (also referred to as Shenzhen Jymed or Jian Yuan) for CNY 1.596 billion, marking its strategic entry into the biomedical sector; its controlling subsidiary Hubei Jianxiang obtained Russian GMP certification and completed construction of 10 peptide API production lines compliant with EU and FDA standards, with further capacity expansions underway.